Cobra attains QC testing accreditation at Swedish plant

Cobra's new 1,000L Hyclone bioreactor at its mammalian cell culture plant in Södertälje
Cobra's new 1,000L Hyclone bioreactor at its mammalian cell culture plant in Södertälje

Related tags Protein

Cobra says it will no longer need to rely on third-parties for its biologics quality control tests after receiving an extension to its GMP certification at a Swedish facility.

The certification awarded by Sweden’s Medical Products Agency (Läkemedelsverket) builds on current GMP for biologics at Cobra’s mammalian antibody and recombinant protein production facility in Södertälje, adding the quality control (QC) testing of registered products.

This means the plant can now offer commercial QC testing as either a standalone product or as part of a full biologics manufacturing contract, and is anticipated to boost business, according to Cobra spokesperson Lara Jupp.

Jupp told that currently QC testing at Cobra's facility in Matfors, Sweden (acquired as part of the Unitech Pharma Group takeover​ in 2011), is outsourced to a third party. However, she said, “going forward we endeavour to increase the independence of Cobra’s Quality Control, and internalise these services utilising our own operational capabilities.”

QC analysis and testing for biologics is more challenging than with small molecule drugs, Jupp continued, due to the complexity of the material and interaction with buffer systems. “Many traditional and newly developed analytical techniques need to be employed in order to characterise and understand biologics material.”

Furthermore, “biologic materials also require consideration of factors, such as environmental impact, that may impact stability (shelf life) or activity.”

The facility – which already has approval for the manufacture of active substances by culturing mammalian cells, the storage of both mammalian and microbial cell banks, and the release testing of protein for clinical trials – recently added a new 1,000L bioreactor in response to growing customer demand.

During a visit to the facility in November by​, site manager Ulrike Ljungkvist said the firm had opted for Thermo Fisher’s Hyclone bioreactor at the site in order to shorten production lead times, and the validation work should be completed next month.

Talks with the MHRA

The contract manufacturer also spoke to us about its ambition for its small scale DNA and microbial facility in Keele, UK.

“It is our aim to enhance the site's capability by expanding the Manufacturing Licence to cover the manufacture and testing of both clinical and commercial products,”​ said Claire Docksey, Head of QA and Qualified Person (QP).

“An initial, favourable discussion has taken place with the MHRA, with final approval dependent on implementation of a full commercial systems infrastructure.”

Related news

Show more

Related products

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

The Complete Guide to eRegulatory and eSource

The Complete Guide to eRegulatory and eSource

Content provided by Florence Healthcare | 01-Apr-2023 | Insight Guide

Shifting to eRegulatory and eSource workflows is a requirement for clinical trial sites to continue to scale and grow their studies. This guide is designed...

Follow us